Exciting new research by Baker Heart and Diabetes Institute researchers raises the possibility that we could reduce the severity of heart failure and ...

The FDA has granted fast-track designation to nipocalimab for the treatment of Sjögren’s disease, according to a press ...

Zhittya Genesis Medicine proudly announces that Dr. Jack Jacobs, President and Chief Science Officer, will be honored by NevadaBio at its Annual Awards Dinner on Wednesday, April 2, 2025, at 5:30 pm ...

The convergence of AI and drug delivery is opening new frontiers in precision medicine. AI-powered predictive modeling is ...

Breakthrough T1D Canada is calling on the Quebec government to adopt the 2022 INESSS recommendation to eliminate current age restrictions on public coverage of insulin pumps and extend access to all ...

Scientists have discovered how cells initiate waste recycling and form ‘garbage bags,’ a crucial process for health. This ...

FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever ...

Johnson & Johnson announced that the U.S. FDA has granted investigational nipocalimab Fast Track designation for the treatment of adult ...

Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction.

Johnson & Johnson's nipocalimab earns FDA Fast Track status for Sjögren's disease, speeding development and review for unmet medical needs.

The renovations at the state's biggest health system will help create the Mass General Brigham Cancer Institute.

A Japanese research team found that the oxidized form of glutathione (GSSG) may protect heart tissue by modifying a key ...